Han Xu, M.d., Ph.d., Fapcr, Sponsor-investigator, Irb Chair

This early-stage trial tests a biologic treatment for 20 people with moderate COVID-19 who also have controlled cancer. The treatment aims to help the immune system recognize and kill the virus. Researchers will check if the virus clears and if the immune response improves.

This early phase trial tests a biological product mix designed to train the immune system to recognize and kill CEA-positive rectal cancer cells. The study involves 20 participants with early-stage rectal cancer (Stage 0 to IIA) who have not yet developed symptoms or metastasis. …

This early-phase trial tests a biological product mix designed to train the immune system to recognize and clear multiple strains of HPV. The study involves 20 participants with cervical HPV infection who do not have symptoms or signs of cancer. The treatment is given through the…

This early-phase trial tests a combination of HIV GP160 protein and BCG vaccine (used for tuberculosis) in 20 HIV-positive people without AIDS symptoms. The goal is to see if the mix can activate the immune system to recognize and kill HIV. It is a small proof-of-concept study, n…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This study examines how genetic variations (SNPs) in certain genes influence how well the drug raloxifene works and its side effects in 600 patients with lobular carcinoma in situ (LCIS), a high-risk breast condition. Participants take raloxifene daily, and researchers sequence t…

This study looks at how genetic differences (SNPs) in drug targets influence how well topotecan works and its side effects in 600 people with small cell lung cancer. Participants are randomly assigned to receive either the usual topotecan capsule or an imported version. Researche…